CA3167644A1 - Teriparatide-containing liquid pharmaceutical composition having excellent pharmacokinetics and/or safety - Google Patents

Teriparatide-containing liquid pharmaceutical composition having excellent pharmacokinetics and/or safety Download PDF

Info

Publication number
CA3167644A1
CA3167644A1 CA3167644A CA3167644A CA3167644A1 CA 3167644 A1 CA3167644 A1 CA 3167644A1 CA 3167644 A CA3167644 A CA 3167644A CA 3167644 A CA3167644 A CA 3167644A CA 3167644 A1 CA3167644 A1 CA 3167644A1
Authority
CA
Canada
Prior art keywords
formulation
liquid pharmaceutical
component
teriparatide
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3167644A
Other languages
English (en)
French (fr)
Inventor
Kohei MIYABE
Atsushi OSE
Yuki Sato
Toshiyuki Kodama
Yasuhiro MATSUNAWA
Hikaru Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Pharma Corp
Original Assignee
Kodama Toshiyuki
Matsunawa Yasuhiro
Ose Atsushi
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kodama Toshiyuki, Matsunawa Yasuhiro, Ose Atsushi, Asahi Kasei Pharma Corp filed Critical Kodama Toshiyuki
Publication of CA3167644A1 publication Critical patent/CA3167644A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3167644A 2017-09-22 2018-09-20 Teriparatide-containing liquid pharmaceutical composition having excellent pharmacokinetics and/or safety Pending CA3167644A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017-182615 2017-09-22
JP2017182615 2017-09-22
CA3075984A CA3075984C (en) 2017-09-22 2018-09-20 LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TERIPARATIDE WITH EXCELLENT PHARMACOKINETIC AND/OR SAFETY PROPERTIES

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3075984A Division CA3075984C (en) 2017-09-22 2018-09-20 LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TERIPARATIDE WITH EXCELLENT PHARMACOKINETIC AND/OR SAFETY PROPERTIES

Publications (1)

Publication Number Publication Date
CA3167644A1 true CA3167644A1 (en) 2019-03-28

Family

ID=65811294

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3167644A Pending CA3167644A1 (en) 2017-09-22 2018-09-20 Teriparatide-containing liquid pharmaceutical composition having excellent pharmacokinetics and/or safety
CA3075984A Active CA3075984C (en) 2017-09-22 2018-09-20 LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TERIPARATIDE WITH EXCELLENT PHARMACOKINETIC AND/OR SAFETY PROPERTIES

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3075984A Active CA3075984C (en) 2017-09-22 2018-09-20 LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TERIPARATIDE WITH EXCELLENT PHARMACOKINETIC AND/OR SAFETY PROPERTIES

Country Status (6)

Country Link
US (1) US20200289622A1 (https=)
EP (1) EP3685850A4 (https=)
JP (6) JP6637220B2 (https=)
CN (1) CN111032073A (https=)
CA (2) CA3167644A1 (https=)
WO (1) WO2019059303A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6618139B1 (ja) * 2018-10-29 2019-12-11 旭化成ファーマ株式会社 週２回の頻度でテリパラチド又はその塩を投与することを特徴とする、骨粗鬆症の予防又は治療方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6357527A (ja) 1986-08-28 1988-03-12 Toyo Jozo Co Ltd 薬剤の吸着防止方法
JPH0669956B2 (ja) 1988-09-30 1994-09-07 旭化成工業株式会社 ポリペプタイド類の吸着防止剤
JP2662842B2 (ja) 1991-12-09 1997-10-15 旭化成工業株式会社 パラサイロイドホルモンの安定化組成物
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
AU785444B2 (en) 2000-05-19 2007-06-14 Jefferson Pharmaceuticals, Llc Peptide pharmaceutical formulations
JP4931306B2 (ja) * 2001-09-27 2012-05-16 旭化成ファーマ株式会社 骨形成を安全に促進させる医薬複合剤
JP4252260B2 (ja) * 2002-06-05 2009-04-08 旭化成ファーマ株式会社 Ｐｔｈの安定化水溶液注射剤
AU2003217243A1 (en) * 2003-01-24 2004-08-23 Thomas J. Gardella Conformationally constrained parathyroid hormone (pth) analogs with lactam bridges
JP4707327B2 (ja) 2004-01-27 2011-06-22 旭化成ファーマ株式会社 ポリペプタイド類の吸着防止剤
CN101022822B (zh) 2004-08-24 2012-06-27 第一三共株式会社 生理学活性肽的液体制剂
KR20080059430A (ko) * 2005-10-06 2008-06-27 나스텍 파마수티컬 컴퍼니 인코포레이티드 부갑상선 호르몬 제형 및 그 사용 방법
JP5522879B2 (ja) 2006-01-16 2014-06-18 旭化成ファーマ株式会社 樹脂容器中の生理活性ペプチドの安定性改善方法
JP2010501476A (ja) * 2006-07-31 2010-01-21 ゼロス セラピューティクス， インコーポレイテッド 副甲状腺ホルモン類似体およびその使用方法
ES2662018T3 (es) * 2009-09-09 2018-04-05 Asahi Kasei Pharma Corporation Agente terapéutico/profiláctico que contiene PTH para la osteoporosis, caracterizado porque la PTH se administra una vez por semana en una dosis unitaria de 200 unidades
WO2011139838A2 (en) 2010-04-28 2011-11-10 Zelos Therapeutics, Inc. Intranasal formulations
EP2683364B1 (en) 2011-03-10 2017-01-18 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
WO2012169435A1 (ja) 2011-06-07 2012-12-13 旭化成ファーマ株式会社 高純度ｐｔｈ含有凍結乾燥製剤およびその製造方法
WO2013108235A1 (en) 2012-01-20 2013-07-25 Lupin Limited Stabilized pth formulation
CN103301058A (zh) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 一种特立帕肽注射用组合物及其制备方法和制剂
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
MX2018004192A (es) * 2015-10-09 2018-09-26 Radius Health Inc Formulaciones de análogos de proteína relacionada con la hormona paratiroidea (pthrp), parches transdérmicos de las mismas y usos de las mismas.

Also Published As

Publication number Publication date
JP2020040998A (ja) 2020-03-19
JP6637220B2 (ja) 2020-01-29
CA3075984A1 (en) 2019-03-28
US20200289622A1 (en) 2020-09-17
JP2021167354A (ja) 2021-10-21
JP2023082167A (ja) 2023-06-13
CA3075984C (en) 2024-10-01
EP3685850A1 (en) 2020-07-29
EP3685850A4 (en) 2021-06-16
JPWO2019059303A1 (ja) 2019-11-14
JP2026063281A (ja) 2026-04-10
JP2024086815A (ja) 2024-06-28
WO2019059303A1 (ja) 2019-03-28
CN111032073A (zh) 2020-04-17

Similar Documents

Publication Publication Date Title
CN110087674B (zh) 含胰岛素的药物组合物
KR20240060873A (ko) Gip/glp1 작용제 조성물
JP5981538B2 (ja) Ｆｇｆ−１８の凍結乾燥製剤
JP7566730B2 (ja) グルカゴン様ペプチド－２（ｇｌｐ－２）類似体の製剤
WO2013186230A1 (en) Pharmaceutical formulation for a therapeutic antibody
BRPI1014760B1 (pt) Preparação compreendendo insulina, nicotinamida e arginina
KR102837765B1 (ko) 아밀린 유사체의 액체 제제
US20230414698A1 (en) Collagen 7 compositions and methods of using the same
TWI837615B (zh) 含腸促胰島素(incretin)類似物之組合物及其用途
WO2019008033A1 (en) METHODS AND MEDICAL USES RELATING TO THE TREATMENT OF HYPOGLYCEMIA
JP2026063281A (ja) 薬物動態及び／又は安全性に優れるテリパラチド含有液状医薬組成物
KR20240034761A (ko) Glp-1r 효능제를 포함하는 약제학적 조성물
JP2015038111A (ja) Ｇ−ｃｓｆの液体製剤
HK40017160A (en) Teriparatide-containing liquid pharmaceutical composition having excellent pharmacodynamics and/or stability
TW201601741A (zh) 用於治療ｅｓｒｄ病患之ｐｅｗ的肌肉生長抑制素拮抗劑

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220714